Key result
High serum thrombomodulin levels in soft tissue sarcoma patients were associated with significantly worse 5-year metastasis-free survival compared to low levels (40.0% vs 81.1%; HR 4.37, p=0.0147).
Why the study?
Soluble thrombomodulin is involved in anticoagulation and related to metastasis, but its correlation with clinicopathological parameters in soft tissue tumors required clarification.
Does high serum thrombomodulin predict metastasis and poor prognosis in patients with soft tissue sarcomas?
Observational (n=135)
Does high serum thrombomodulin predict metastasis and poor prognosis in patients with soft tissue sarcomas?
Hazard Ratio: 4.37
Absolute Event Rate: 40% vs 81.1%
p-value: p=0.0147
High levels of soluble thrombomodulin may serve as a significant predictor of metastasis and poor prognosis in patients with soft tissue sarcomas.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for thrombomodulin as prognostic marker in soft tissue sarcoma; should not yet change practice.
Asanuma et al. (2019) conducted an observational in Soft tissue sarcomas (n=135). High serum thrombomodulin levels vs. Low serum thrombomodulin levels was evaluated on 5-year metastasis-free survival (HR 4.37, p=0.0147). High serum thrombomodulin levels in soft tissue sarcoma patients were associated with significantly worse 5-year metastasis-free survival compared to low levels (40.0% vs 81.1%; HR 4.37, p=0.0147).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: